Medical Clinic II Gastroenterology, University Hospital Bucharest, Carol Davila University of Medicine and Pharmacy, 7001, Bucharest, Romania.
Department of Cardiology, Bagdasar-Arseni Emergency Clinical Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
Cell Biol Toxicol. 2017 Feb;33(1):5-14. doi: 10.1007/s10565-016-9361-x. Epub 2016 Sep 28.
Nonalcoholic fatty liver disease (NAFLD) is very prevalent and now considered the most common cause of chronic liver disease. Staging the severity of liver damage is very important because the prognosis of NAFLD is highly variable. The long-term prognosis of patients with NAFLD remains incompletely elucidated. Even though the annual fibrosis progression rate is significantly higher in patients with nonalcoholic hepatitis (NASH), both types of NAFLD (nonalcoholic fatty liver and nonalcoholic steatohepatitis) can lead to fibrosis. The risk for progressive liver damage and poor outcomes is assessed by staging the severity of liver injury and liver fibrosis. Algorithms (scores) that incorporate various standard clinical and laboratory parameters alongside imaging-based approaches that assess liver stiffness are helpful in predicting advanced fibrosis.
非酒精性脂肪性肝病（NAFLD）非常普遍，现在被认为是慢性肝病的最常见原因。对肝损伤严重程度进行分期非常重要，因为 NAFLD 的预后差异很大。NAFLD 患者的长期预后仍不完全清楚。尽管非酒精性肝炎（NASH）患者的纤维化进展年发生率明显更高，但两种类型的 NAFLD（非酒精性脂肪肝和非酒精性脂肪性肝炎）都可导致纤维化。通过分期评估肝损伤和肝纤维化的严重程度，可以评估进行性肝损伤和不良结局的风险。纳入各种标准临床和实验室参数的算法（评分）以及评估肝硬度的基于影像学的方法有助于预测晚期纤维化。
